Kornimate/medical-research-clean huggingface dataset:
in home vr therapy

Conditions: Stroke

Summary: virtual reality is a video game in which a person and their real-time movements are represented on a screen in a virtual environment. this study will compare the use of multi-user virtual reality (vr) to single-user vr to determine if either provides superior engagement in upper extremity therapy and greater motivation to perform repetitive training. stroke survivors will participate in a longitudinal study in which they will have the opportunity to perform rehabilitative training with multi-user vr and single-user vr modes in their homes. they will use each mode for 2 weeks, completing 4 session per week, each session is 1 hour long. upper extremity motor control, level of engagement, and active range of motion will be assessed at time points during the intervention period. subject evaluations will take place before the intervention, at the midpoint of intervention (between switching from multi-user to single-user modes, or vice versa), and at the end of the intervention. the investigators hope to address two aims: aim 1: to determine if the use in-home multi-user virtual reality treatment results in greater engagement in therapy compared with in-home single user virtual reality treatment. aim 2: to determine if in-home virtual reality treatment results in greater practice the investigators hypothesize that stroke survivors will be more engaged in therapy when training with the multi-user vr system and this will translate into greater practice.


Eligibility criteria:
inclusion criteria: * are between the ages of 21 and 80 * experienced a single stroke at least 6 months prior to enrollment * have moderate arm impairment as indicated by a score between 4 and 6 on the chedoke-mcmaster stroke assessment, arm subscale * live within 20 miles of the rehabilitation institute of chicago (as study personnel will need to travel to their home) exclusion criteria: * other neurological, neuromuscular, or orthopedic disease * pain in the upper extremity with movements required in the treatment * contracture that limits use of the vr system * vision problems which would preclude the ability to use the vr system * cognitive or language deficits that would prevent them from understanding the tasks * concurrent enrollment in another intervention study involving the affected arm or hand * botox injection in the arm within the previous 6 months

Keywords: stroke virtual reality therapy rehabilitation upper extremity arm telerehabilitation
endostatin combined with chemotherapy for adjuvant treatment of esophageal cancer

Conditions: Esophageal Cancer

Summary: this is an open-label, randomized trial, it compares the efficacy and safety between apatinib combined chemotheray and chemotherapy for adjuvant treatment of esophageal cancer


Eligibility criteria:
inclusion criteria: * iia-iiic phase esophageal squamous cell carcinoma confirmed by histopathology and immunohistochemistry. * r0 resection has been performed at least before 4 weeks. * ecog ps score: 0-1 points. * estimated survival time: at least 12 weeks. * no radiotherapy, chemotherapy or molecular targeted therapy before. * main organs are functional, which meet the following criteria: blood routine: hb≥90 g/l（no blood transfusion within 14 days）, anc≥1.5×109/l, plt ≥80×109/l. biochemical examination： alb≥30g / l（no blood transfusion within 14 days）, alt\<2uln； ast\<2uln tbil≤1.5uln； plasma cr≤1.5uln； * volunteer with signed informed consent form, good compliance and good follow-up cooperation. * patients who the investigator believws they can benefit. exclusion criteria: * those who have had other malignant tumors in the past or at the same time. * pregnant or lactating women. * patients with grade-ii or higher myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including qtc interval ≥ 450 ms) and cardiac dysfunction according to nyha criteria iii to iv. cardiac color doppler examination: lvef (left ventricular ejection) score) \<50%. * have clear gastrointestinal bleeding concerns (such as local active ulcer lesions, fecal occult blood ++), and a history of gastrointestinal bleeding within 6 months. * have a history of mental illness or psychotropic substance abuse. * patients who have participated in other drug clinical trials within 4 weeks. * according to the investigator's judgment, patients who are at a risk or have accompanying disease. * patients who believe that they are unsuitable for inclusion.
a study of 18f-alf-nota-neurotensin pet/ct for imaging prostate cancer

Conditions: Prostate Cancer

Summary: the aim of this study is to investigate the clinical value of \[18f\]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-neurotensin（18f-alf-nota-neurotensin）positron emission tomography / computed tomography (pet/ct) in patients with prostate cancer (pca).

18f-alf-nota-neurotensin is a radioligand targeting the neurotensinreceptor, which is widely expressed on the cell surface of pca. the radioligand can be used for the diagnosis and stage of the pca. a total of 5 volunteers and 60 pca patients will be subjected to a 18f-alf-nota-neurotensin pet/ct scan. the uptake of 18f-alf-nota-neurotensin in organs and tumor lesions will be quantified as standardized uptake values (suvmax/suvmean).

Eligibility criteria:
inclusion criteria: 1. histologically and/or clinically confirmed and/or suspicious of pca. 2. signed informed consent. exclusion criteria: claustrophobia (unable to accept pet/ct scanning)

Keywords: 18f-alf-nota-neurotensin
phase ii clinical study of shr-a1811 in patients with her2 expression / amplification of locally advanced unresectable or recurrent metastatic biliary tract cancer

Conditions: HER2 Expression / Amplification in Patients With Biliary Tract Cancer

Summary: this study was to evaluate the efficacy and safety of shr-a1811 in patients with locally advanced unresectable or recurrent metastatic btc with her2 expression / amplification who failed first-line or second-line systemic treatment.


Eligibility criteria:
inclusion criteria: 1. age 18-75 years old ( including both ends ), male or female ; 2. ecog-ps score : 0 or 1; 3. expected survival ≥ 12 weeks; 4. subjects with locally advanced or recurrent metastatic biliary tract cancer diagnosed by histopathology or cytology are not suitable for surgical resection, transplantation or ablation; 5. subjects who failed or intolerance after systemic chemotherapies; 6. according to the recist v1.1 standard, the subjects had at least one measurable lesion； 7. the main organ function is normal, in line with the program requirements ; 8. if the patient has active hepatitis b virus ( hbv ) infection : hbv-dna must be \< 500 iu / ml； 9. consent to contraception. exclusion criteria: 1. received anti-tumor treatment such as chemotherapy, radiotherapy, immunotherapy, biotherapy or other clinical research drugs within 4 weeks before the first administration; 2. subjects with a history or evidence of brain metastasis or meningeal metastasis ; 3. with acute or chronic uncontrolled pancreatitis or child-pugh liver function grade c ; 4. severe trauma or major surgery was performed within 4 weeks before the first administration; 5. to study the severe heart disease within 6 months before the first administration ; 6. patients with clinical symptoms and uncontrolled moderate and above pleural effusion, ascites or pericardial effusion, requiring therapeutic puncture drainage ; 7. severe infection symptoms occurred within 2 weeks before the first administration; 8. known hereditary or acquired bleeding and thrombotic tendency ; 9. congenital or acquired immune defects; 10. the subjects had severe and uncontrollable concomitant diseases; 11. cerebral infarction, pulmonary embolism or deep vein thrombosis occurred within 6 months before the first administration of the study;
diabetes self-management education with sleep hygiene

Conditions: Diabetes Mellitus, Type 2; Sleep Hygiene

Summary: this study will test whether adding sleep hygiene education and support to diabetes self-management education and support (dsmes) in diverse patients (african american, hispanic, pacific islander, and caucasian) with type 2 diabetes myelitis (t2dm) from rural uams regional programs clinics is more effective than dsmes alone. the specific aims for this study are: * aim 1a (primary): determine if this model improves blood glucose levels as measured by the hba1c test in diverse adults with t2dm. * aim 1b: determine the preliminary effectiveness of dsmes+shes on sleep duration and sleep quality, blood pressure, fasting lipids, body mass index (bmi), self-management behavior, self-efficacy, diabetes-related distress, and diabetes-related quality of life in diverse adults with t2dm. * aim 2a: determine the feasibility and acceptability of dsmes+ shes when implemented with diverse adults with t2dm. * aim 2b: determine the feasibility and acceptability of dsmes+ shes implementation in regional programs clinics.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * diagnosed with type 2 diabetes * speak english exclusion criteria: * received dsme in the past three years * have a condition that makes it unlikely they will be able to follow the protocol
transversus abdominis plan block versus rectus sheath block

Conditions: Abdominal Obesity; Postoperative Pain; Postoperative Complications

Summary: the investigator aims to compare the analgesic efficacy of transversus abdominis plan block and rectus sheath block which are used to prevent intraoperative and postoperative pain and reduce the use of opioid in abdominoplasty operations.

abdominoplasty is a frequently performed surgical procedure in aesthetic and plastic surgery. it is performed to solve the pain caused by the large abdomen, respiratory distress and aesthetic problems. since large tissue excision is made and a large area is worked on, providing perioperative pain control is also important to prevent both postoperative respiratory distress and postoperative chronic pain formation. in order to prevent both intraoperative and postoperative pain and to reduce opioid use, peripheral nerve blocks that provide analgesia on the abdominal wall can be applied to patients before the surgical incision. the most well-known of these blocks is the transversus abdominis plane block. another block that has been proven effective in abdominal surgery is the rectus sheath block. in the transversus abdominis plane block (tap), local anesthetic is injected into the fascia between the internal oblique and transversus abdominis muscles, aiming for analgesia. it provides multidermatomal sensory block by spreading the local anesthetic agent in the fascial area. the rectus sheath (rk) block is also a preferred plan block in abdominoplasty surgery. in this block, local anesthetic agent is injected between the rectus muscle and the posterior rectus sheath to achieve analgesia. although the effectiveness of both blocks has been shown mostly in abdominoplasty operations, there is no publication in the literature showing and comparing their effectiveness in abdominoplasty operations. with this study, the investigator aimed to compare the analgesic effectiveness of the two blocks in patients who will undergo abdominoplasty operations.

Eligibility criteria:
inclusion criteria: patients who will undergo elective abdominoplasty * patients between the ages of 18-65 * asa (american society of anesthesiologists) i-ii-iii patients * patients with a body weight between 50-80 kg exclusion criteria: * - asa iv patient group * patients under 18 years of age * patients without cooperation * patients with chronic alcohol use * patients in whom peripheral plane block application is contraindicated (infection at the application site, coagulopathy, local anesthetic allergy) * patients who do not want to participate in the study

Keywords: post operative pain transversus abdominis plane block rectus sheat block
randomized controlled trial comparing the efficacy and safety of fmt in hepatitis b reactivation leads to acute on chronic liver failure.

Conditions: Acute on Chronic Liver Failure

Summary: data for stool microbiome will be collected for all the chronic hepatitis b subjects (pre cirrhotic,compensated,decompensated and reactivation). all the in and out patient with hepatitis b reactivation will be recruited and randomized into two arms. group 1 tenofovir group 2 tenofovir with fmt (fecal microbiota transplant). tenofovir would be given 300 mg once daily fmt through nj (naso-jejunal) tube for 7 days.


Eligibility criteria:
inclusion criteria: 1. reactivation of chronic hepatitis b virus leads to acute on chronic liver failure- (meld (model for end stage liver disease) \>18 years. 2. 18-75 yr both male and female 3. chronic hepatitis b patient (precirrhotic,compensated,decompensated). 4. healthy adult family member of the patient will be taken as a control. exclusion criteria: * acute on chronic liver failure due to other causes -alcohol,hepatitis a virus,hepatitis e virus,hsv (herpes simplex virus),cmv (cytomegalovirus),ebv (epstein-barr virus) other hepatotropic virus,drugs,cam. * active gastrointestinal bleeding * intracranial bleeding * multi-organ failure (\>2) on mechanical ventilation * sofa score \>2 * on high inotropic support * paralytic ileus * pregnancy * hepatocellular carcinoma * antibiotic,probiotic within last 3 months
mk0524a bioequivalence study (0524a-059)

Conditions: Dyslipidemia

Summary: this study will evaluate the definitive bioequivalence of tablets of mk0524a (1000 mg extended release (er) niacin/ 20 mg laropiprant) from two sources.


Eligibility criteria:
inclusion criteria: * subject is in good health * subject is willing to follow all study guidelines exclusion criteria: * subject has or has a history of any disease or condition that might confound the results of the study or make participation unsafe
memantine in body focused repetitive behaviors

Conditions: Trichotillomania (Hair-Pulling Disorder); Dermatillomania

Summary: this study is 8 weeks long and involves subjects taking memantine or placebo. if they are randomly assigned to the memantine arm and are eligible to participate in the study, they will begin by taking 10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks. efficacy and safety measures will be performed at each visit. participants will be randomized to receive either memantine or placebo on a 1:1 basis. this blinding will be maintained by the ids pharmacy at the university of chicago.

the goal of the proposed study is to evaluate the efficacy and safety of memantine in 100 subjects with dsm-5 trichotillomania (ttm) or skin picking disorder (spd). the hypothesis to be tested is that memantine will be more effective and well tolerated in adults with trichotillomania or skin picking disorder compared to placebo. the proposed study will provide needed data on the treatment of a disabling disorder where there are not any current treatments options. this will be one of few studies assessing the use of pharmacotherapy for the treatment of ttm and spd in adults. assessing the efficacy and safety of memantine will help inform clinicians about additional treatment options for adults suffering from this disorder.

Eligibility criteria:
inclusion criteria: 1. men and women age ≥18 years; 2. current dsm-5 trichotillomania or skin picking disorder; and 3. ability to understand and sign the consent form. exclusion criteria: 1. unstable medical illness based on history or clinically significant abnormalities on baseline physical examination 2. current pregnancy or lactation, or inadequate contraception in women of childbearing potential 3. subjects considered an immediate suicide risk based on the columbia suicide severity rating scale (c-ssrs) (www.cssrs.columbia.edu/docs) 4. past 12-month dsm-5 diagnosis of psychosis, bipolar disorder, mania, or a substance or alcohol use disorder 5. illegal substance use based on urine toxicology screening 6. stable dose of medications for at least the past 3 months 7. previous treatment with memantine 8. cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent
reducing right ventricular failure in pulmonary arterial hypertension (relieve-pah)

Conditions: Pulmonary Arterial Hypertension

Summary: the objectives of the relieve-pah study are to obtain first-in-human experience with the study device in patients with severe pulmonary arterial hypertension, including evidence of initial safety, device performance and possible signals of clinical effectiveness.

this is a multi-national, multi-center, prospective, non-randomized, open label trial of patients implanted with the study device. a total of up to 20 patients will be implanted with the study device and followed at regular intervals for 1 year and then annually for a total of 5 years post implant.

Eligibility criteria:
main inclusion criteria: 1. group 1 pah (idiopathic, connective tissue disease, hiv, corrected congenital heart disease). 2. who functional class iii or iv symptoms. if who class iii, at least 1 high-risk characteristic or 2 intermediate-risk characteristics from the 2015 esc guidelines. 3. receiving maximal available and tolerable pharmacological pah therapy ≥3 months at a stable dose for ≥1 month. main exclusion criteria: 1. resting oxygen saturation \<90 % without supplemental oxygen corrected for altitude. 2. mean right atrial pressure \>20 mmhg. 3. severe restrictive or obstructive lung disease. 4. evidence of organ dysfunction other than right heart failure. 5. left ventricular ejection fraction \<40 %. 6. anatomical anomaly on transesophageal echocardiography or intracardiac echocardiography that precludes implantation of shunt across fossa ovalis (fo) of the interatrial septum. 7. inadequate vascular access for implantation of shunt, e.g. femoral venous access for transseptal catheterization and inferior vena cava (ivc) is not patent. 8. hemodynamic heart rhythm, or respiratory instability at time of final exclusion criteria.

Keywords: pulmonary arterial hypertension pah interatrial shunt interatrial shunting atrial septostomy
nasal septum deviation may affect facial morphologic parameters.

Conditions: Nasal Septal Deviation

Summary: the aim of the study is to evaluate the relationship between the direction and degree of nasal septal deviation with nasal bone morphology , along with factors such as age and gender.

the nasal septum is located in the middle of the nasal cavity and it forms the major part of the nose structure. it is divided into a posterior part by the vomer and perpendicular plate of the ethmoid bone and an anterior part by the quadrangular cartilage . in the growth period, the nasal septum acts as a growth plate that affects surrounding bones and facial skeletal tissues .thus, nasal septum deviation affects facial morphologic parameters such as interalveolar distance and maxillary rotation distance, causing compensatory changes in the lateral nasal wall and septal deviation,which are associated with nasal floor and palatal region asymmetries . nasal septum deviation is the most common anatomic variation in up to 80% of healthy adults . from the initial growth stages, the maxillary bone and nasal structure have significant anatomic connections because of their close embryologic development. the severity of septal deviation also affects the ipsilateral lateral lamina of the cribriform plate width and ipsilateral middle turbinate length . nasal septal deviation may affect nasal bone growth and facial morphology .knowledge of nasal morphologic parameters plays an important role in planning successful rhinoplasty and septoplasty operations. some morphological characteristics of the nose such as bone length and thickness may present different forms according to factors correlated with age, gender, climate and race.

Eligibility criteria:
inclusion criteria: * patients over 18 years old who attending to ear,nose and throat department out patients complaining of nasal septum deviation causing nasal symptoms are exposed to maxillofacial ct. exclusion criteria: 1. patients with a history of rhinoplasty, 2. patients with cranial and facial trauma or bone deformity (e.g. s-shaped septum deviation). 3. patients with a mass or polyp in the nasal cavity. 4. patients with adenoid . 5. patients with nasopharyngeal lesions. 6. patients with craniofacial anomalies.
exercise and bright light treatment: effects on body weight and composition

Conditions: Obesity; Fatigue

Summary: bright light therapy has been used to safely and effectively treat conditions such as seasonal affective disorder and to regularize sleep in patients with circadian rhythm disorder. based on evidence of the link between bright light, serotonin, mood and carbohydrate metabolism, it has been suggested that bright light therapy can improve weight loss but the literature on the subject is sparse. further, the literature suggests that apart from any changes in mood and carbohydrate metabolism, bright light may reduce the unpleasant side-effects of exercise and increase compliance to an exercise program.

objective: increased physical activity is important given the concern over the growing rates of obesity. bright light therapy has the potential to enhancing serotonin levels, impact on carbohydrate metabolism and reducing soreness and hyperthermia associated with physical activity. the aim of this study is to conduct a controlled investigation of the effects of bright light therapy and exercise on weight loss and body composition in overweight individuals. research methods and procedures: twenty-five overweight male and female subjects will be assigned to 6 weeks of moderate exercise with or without bright light treatment. outcome measure included changes in body mass and body composition and ratings of mood, seasonality and sleep.

Eligibility criteria:
inclusion criteria: * overweight subjects * subjects in otherwise good health * subjects willing to participate in a 6-week moderate exercise program * bedtime between 10pm and 12am; wake-up time between 6am and 8am * score in the median range of the morningness/ eveningness questionnaire (i.e., subjects show no distinct characteristics of phase delay or phase advance) exclusion criteria: * progressive eye disease * history of cataracts, macular degeneration or have undergone laser corrective eye surgery in the past 30 days. * currently taking any medications, e.g. antibiotics, tricyclic antidepressants, that may affect photosensitivity * history of heart disease * history of respiratory diseases, such as asthma, emphysema * any severe or uncontrolled general medical condition * severe psychiatric disorder (as determined by psychiatrist - cms) * history of mania * grossly obese individuals with morbid obesity

Keywords: bright light treatment exercise body fat index mood sleep fatigue
effect of nutritional intervention on the lipid profile of hiv-positive patients who start haart: a randomized trial

Conditions: HIV Infections

Summary: highly active antiretroviral therapy (haart) in hiv-positive patients is associated with the development of dyslipidemia, a risk factor for cardiovascular events. the objective of this study was to evaluate the effect of dietary intervention in individuals who start haart.

adult patients prescribed to haart that met the exclusion criteria were consecutively enrolled in a randomized trial: * control (receiving general guidelines on dietary education) * intervention (receiving general guidelines on dietary education and nutritional follow-up every 3 months)

Eligibility criteria:
inclusion criteria: * hiv-positive individuals naive to haart, with clinical indication to start therapy exclusion criteria: * diabetes mellitus * pregnancy * active opportunistic disease * any mental deficiency * use of lipid profile influencing drugs * use of illicit drugs

Keywords: hiv haart nutrition dyslipidemia